SENSITIVITY TO CONVENTIONAL CHEMOTHERAPEUTIC DRUGS ACCORDING TO ARID1A DEFICIENCY OF OVARIAN CLEAR CELL CARCINOMA AND ENDOMETRIOID CARCINOMA CELLS

被引：0
|
作者：
Kuroda, T. [1 ,2 ]
Ogiwara, H. [1 ]
Takahashi, K. [1 ,2 ]
Sasaki, M. [1 ]
Yoshida, H. [3 ]
Kato, T. [4 ]
Okamoto, A. [2 ]
Kohno, T. [1 ]
机构：
[1] Natl Canc Ctr, Div Genome Biol, Res Inst, Tokyo, Japan
[2] Jikei Univ, Dept Obstet & Gynecol, Sch Med, Tokyo, Japan
[3] Natl Canc Ctr, Dept Pathol & Clin Labs, Tokyo, Japan
[4] Natl Canc Ctr, Dept Gynecol, Tokyo, Japan
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2018年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCS8-0330
引用
收藏
页码：180 / 180
页数：1
相关论文
共 50 条
  • [21] Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma
    Xiao, Wenbin
    Awadallah, Amad
    Xin, Wei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2012, 5 (07): : 642 - 650
  • [22] Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinoma
    Ge, Huijuan
    Xiao, Yaoxin
    Qin, Guangqi
    Gu, Yanzi
    Cai, Xu
    Jiang, Wenhua
    Tu, Xiaoyu
    Yang, Wentao
    Bi, Rui
    DIAGNOSTIC PATHOLOGY, 2021, 16 (01)
  • [23] Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinoma
    Huijuan Ge
    Yaoxin Xiao
    Guangqi Qin
    Yanzi Gu
    Xu Cai
    Wenhua Jiang
    Xiaoyu Tu
    Wentao Yang
    Rui Bi
    Diagnostic Pathology, 16
  • [24] THE ARID 1A PATHWAY IN OVARIAN CLEAR CELL AND ENDOMETRIOID CARCINOMA, IN CONTIGUOUS ENDOMETRIOSIS AND IN BENIGN ENDOMETRIOSIS
    Chene, G.
    Ouellet, V.
    Rahimi, K.
    Barres, V.
    Caceres, K.
    Meunier, L.
    Cyr, L.
    De ladurantaye, M.
    Provencher, D.
    Masson, A. M. Mes
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 959 - 960
  • [25] The ARID1A, p53 and β-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium
    Heckl, Marlene
    Schmoeckel, Elisa
    Hertlein, Linda
    Rottmann, Miriam
    Jeschke, Udo
    Mayr, Doris
    PLOS ONE, 2018, 13 (02):
  • [26] Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutations
    Bitler, Benjamin G.
    Aird, Katherine M.
    Zhang, Rugang
    MOLECULAR & CELLULAR ONCOLOGY, 2016, 3 (01):
  • [27] Identification of novel biomarkers of response to ATR inhibitors in ARID1A mutant ovarian clear cell carcinoma
    Stewart, J. R.
    Baxter, J.
    Zatreanu, D.
    Brough, R.
    Song, F.
    Konde, A.
    Krastev, D.
    Alexander, J.
    Natrajan, R.
    Pettitt, S.
    Banerjee, S.
    Lord, C.
    ANNALS OF ONCOLOGY, 2022, 33 : S383 - S384
  • [28] HDAC6 AS A THERAPEUTIC TARGET FOR OVARIAN CLEAR CELL CARCINOMA, IN ASSOCIATION WITH ARID1A LOSS
    Yano, M.
    Yasuda, M.
    Miyazawa, M.
    Miwa, M.
    Hasegawa, K.
    Narahara, H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 874 - 874
  • [29] CCNE1 Amplification and Overexpression Characterizes Ovarian Clear Cell Carcinoma But Not Ovarian Endometrioid Carcinoma
    Ayhan, Ayse
    Ogawa, Hiroshi
    Bahadirli-Talbott, Asli
    Wu, Ren-Chin
    Sugimura, Haruhiko
    Wang, Tian-Li
    Shih, Ie-Ming
    MODERN PATHOLOGY, 2015, 28 : 273A - 274A
  • [30] CCNE1 AMPLIFICATION AND OVEREXPRESSION CHARACTERIZE OVARIAN CLEAR CELL CARCINOMA BUT NOT OVARIAN ENDOMETRIOID CARCINOMA
    Ayhan, A.
    Ogawa, H.
    Wu, R. C.
    Sugimura, H.
    Wang, T. L.
    Shih, I. M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 399 - 399
12345